Immunomedics Gets U.S. Patent For Humanized PAM4 Monoclonal Antibody And Its Use In Diagnosis And Therapy Of Pancreatic Cancer - Quick Facts
Tuesday, October 16, 2007; Posted: 09:58 AM
(RTTNews) - Immunomedics, Inc. (
IMMU |
charts |
news |
PowerRating
) on Tuesday said it received U.S. patent for ''Monoclonal antibody hPAM4'' and its use in Diagnosis and Therapy of Pancreatic Cancer. The patent covers the composition of matter for the MUC1-antigen binding humanized antibody and its use in the diagnosis and therapy of pancreatic cancers.
According to the company, the initial clinical results from a Phase I dose-escalation study with hPAM4 labeled with the radioisotope, yttrium-90, in patients with unresectable and metastatic pancreatic cancer were encouraging and the study has completed patient enrollment. A second dose-escalation study using smaller Y-90 doses given repeatedly to patients and in combination with gemcitabine is planned for early 2008.
For comments and feedback: contact editorial@rttnews.com
Copyright(c) 2007 RealTimeTraders.com, Inc. All Rights Reserved
Morning Coffee with TradingMarkets -- Free Newsletter
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
